NCT06276283

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

A Phase II, Single Arm, Multicenter Study to Assess the Safety, Tolerability and Anti-Tumor Efficacy of DZD9008 With Bevacizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations (WU-KONG29)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Dizal Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab.

Detailed description

A phase 2, multicenter study to evaluate the safety, tolerability, and anti-tumor efficacy in patients with locally advanced or metastatic NSCLC harboring EGFR mutations. This study comprises two parts (Part A, dose escalation and Part B, dose expansion). Part A will enroll patients with different EGFR mutations. Only patients with EGFR Exon 20 insertion mutation will be enrolled into Part B.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	DZD9008 plus Bevacizumab	DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks

Timeline

• Start date: 2023-02-15
• Primary completion: 2025-12-31
• Completion: 2026-02-28
• First posted: 2024-02-23
• Last updated: 2025-06-19

Locations

1 site across 1 country: China